These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 23615820)

  • 41. Developments in L2-based human papillomavirus (HPV) vaccines.
    Schellenbacher C; Roden RBS; Kirnbauer R
    Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. STAT-5 Regulates Transcription of the Topoisomerase IIβ-Binding Protein 1 (TopBP1) Gene To Activate the ATR Pathway and Promote Human Papillomavirus Replication.
    Hong S; Cheng S; Iovane A; Laimins LA
    mBio; 2015 Dec; 6(6):e02006-15. PubMed ID: 26695634
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Machine learning prediction of antiviral-HPV protein interactions for anti-HPV pharmacotherapy.
    Lin HH; Zhang QR; Kong X; Zhang L; Zhang Y; Tang Y; Xu H
    Sci Rep; 2021 Dec; 11(1):24367. PubMed ID: 34934067
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IDR-targeting compounds suppress HPV genome replication via disruption of phospho-BRD4 association with DNA damage response factors.
    Wu SY; Lai HT; Sanjib Banerjee N; Ma Z; Santana JF; Wei S; Liu X; Zhang M; Zhan J; Chen H; Posner B; Chen Y; Price DH; Chow LT; Zhou J; Chiang CM
    Mol Cell; 2024 Jan; 84(2):202-220.e15. PubMed ID: 38103559
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The natural history of human papillomavirus infections of the mucosal epithelia.
    Chow LT; Broker TR; Steinberg BM
    APMIS; 2010 Jun; 118(6-7):422-49. PubMed ID: 20553526
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac trial).
    Murray ML; Meadows J; Doré CJ; Copas AJ; Haddow LJ; Lacey C; Jit M; Soldan K; Bennett K; Tetlow M; Nathan M; Gilson R
    BMC Med Res Methodol; 2018 Nov; 18(1):125. PubMed ID: 30400777
    [TBL] [Abstract][Full Text] [Related]  

  • 47. E2 protein is the major determinant of specificity at the human papillomavirus origin of replication.
    Laaneväli A; Ustav M; Ustav E; Piirsoo M
    PLoS One; 2019; 14(10):e0224334. PubMed ID: 31644607
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Persistence of an Oncogenic Papillomavirus Genome Requires
    Van Doorslaer K; Chen D; Chapman S; Khan J; McBride AA
    mBio; 2017 Nov; 8(6):. PubMed ID: 29162712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DNA replication specificity and functional E2 interaction of the E1 proteins of human papillomavirus types 1a and 18 are determined by their carboxyl-terminal halves.
    Gopalakrishnan V; Sheahan L; Khan SA
    Virology; 1999 Apr; 256(2):330-9. PubMed ID: 10191198
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Human papillomaviruses activate the ATM DNA damage pathway for viral genome amplification upon differentiation.
    Moody CA; Laimins LA
    PLoS Pathog; 2009 Oct; 5(10):e1000605. PubMed ID: 19798429
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Control of human papillomavirus type 11 origin of replication by the E2 family of transcription regulatory proteins.
    Chiang CM; Dong G; Broker TR; Chow LT
    J Virol; 1992 Sep; 66(9):5224-31. PubMed ID: 1323690
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay.
    Toots M; Ustav M; Männik A; Mumm K; Tämm K; Tamm T; Ustav E; Ustav M
    PLoS Pathog; 2017 Feb; 13(2):e1006168. PubMed ID: 28182794
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The E1 proteins.
    Bergvall M; Melendy T; Archambault J
    Virology; 2013 Oct; 445(1-2):35-56. PubMed ID: 24029589
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human papillomavirus proteins as prospective therapeutic targets.
    Pang CL; Thierry F
    Microb Pathog; 2013 May; 58():55-65. PubMed ID: 23164805
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of the human papillomavirus type 11 E1 protein with histone H1.
    Swindle CS; Engler JA
    J Virol; 1998 Mar; 72(3):1994-2001. PubMed ID: 9499053
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Papillomavirus infections--a major cause of human cancers.
    zur Hausen H
    Biochim Biophys Acta; 1996 Oct; 1288(2):F55-78. PubMed ID: 8876633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A fifteen-amino-acid peptide inhibits human papillomavirus E1-E2 interaction and human papillomavirus DNA replication in vitro.
    Kasukawa H; Howley PM; Benson JD
    J Virol; 1998 Oct; 72(10):8166-73. PubMed ID: 9733858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interferon-inducible protein, P56, inhibits HPV DNA replication by binding to the viral protein E1.
    Terenzi F; Saikia P; Sen GC
    EMBO J; 2008 Dec; 27(24):3311-21. PubMed ID: 19008854
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interaction of the Human Papillomavirus E1 Helicase with UAF1-USP1 Promotes Unidirectional Theta Replication of Viral Genomes.
    Orav M; Gagnon D; Archambault J
    mBio; 2019 Mar; 10(2):. PubMed ID: 30890612
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Virological and carcinogenic aspects of HPV].
    Prétet JL; Charlot JF; Mougin C
    Bull Acad Natl Med; 2007 Mar; 191(3):611-23; discussion 623. PubMed ID: 18072657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.